Innovation
Caris Molecular Tumor Board Report
From data to decision — redefining tumor board intelligence.
The Caris Molecular Tumor Board Report is an innovative research-use-only (RUO) tumor profiling report that builds on the comprehensive foundation of the Caris Molecular Profiling Report to offer even deeper insights into tumor biology. The Molecular Tumor Board Report enhances the industry-leading capabilities of the standard Caris report, presenting cutting-edge data from Caris molecular profiling in more insightful ways to build the complete molecular blueprint of a patient’s cancer.
Tailored Insights for Every Tumor
The Caris Molecular Tumor Board Report embodies the future of precision oncology. Data from Caris’ AI-enhanced comprehensive molecular profiling is displayed in innovative, easy-to-interpret modular graphs and tables. In addition to pan-tumor reporting modules, the report also features tumor-specific options from its extensive menu.
Visualization Tools for Molecular Data
Pan-Tumor Report Modules Include:
- Next Generation Sequencing (NGS) Metrics
- Tumor Mutational Burden (TMB) Variants
- Enhanced eKaryotype
- Exon-Level Copy Number Alterations
- Relative RNA Expression Heatmap
- Visualization of RNA Fusions
- Immune Cell Deconvolution
Visualization of RNA fusions detected using whole transcriptome sequencing
When Every Insight Counts
Available upon request, the Caris Molecular Tumor Board Report is a powerful tool for molecular tumor boards, case consults, and clinical trial decision-making. The AI-driven insights provided by the Caris Molecular Tumor Board Report can also be leveraged to confirm diagnoses and examine specific genomic features, such as fusions and molecular signatures.
Have Questions?
Discover
More
With one of the largest, multi-modal databases of combined molecular and clinical outcomes data in the world, Caris applies highly sophisticated AI bioinformatics and machine learning capabilities on this massive database to create novel, clinically relevant solutions to classify cancer at the molecular level and predict patient response in ways never before possible.
Caris Life Sciences contributes to the body of research in oncology to advance the understanding of molecular science and further enable the delivery of precision medicine.